
No results matched your search
By Dhirendra Tripathi
Investing.com – Shares of Eli Lilly (NYSE:LLY) were marginally negative as the company’s announcement that the phase 3 study of a drug for treating rheumatoid arthritis in Covid-19 patients had failed to meet its goals left traders disappointed.
Eli’s filing said patients treated with baricitinib were 2.7% less likely than those receiving standard of care to progress to ventilation or death, a difference found to be statistically insignificant.
Baricitinib is approved in the U.S. as a treatment for adults with moderate to severe rheumatoid arthritis and in the EU and Japan for treating atopic dermatitis.
Additional research is ongoing to further evaluate the potential role of baricitinib in Covid-19, the company said.
The pharmaceutical giant will share the data from the study with regulatory authorities in the U.S., the E.U. and other geographies to evaluate next steps for baricitinib.
In the wake of GameStop’s (GME) epic stock run in January, Reddit's WallStreetBets community targeted many other stocks seeking to gain from betting against hedge...
The White House’s proposed $2 trillion infrastructure and economic recovery package is designed to contribute to a speedy recovery from the economic recession experienced...
Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Consumer Goods, Industrials and Financials sectors led shares higher while losses in the Oil &...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.